Headquarters

USA

Every company in the roster headquartered in USA.

Views

165 of 165 companies

Company	Pipeline	Most advanced	Next readout
PfizerPFE · NYSE	76 assets: 41 approved, 11 Ph 3, 14 Ph 2, 10 Ph 1	TavapadonPhase 3 · Parkinson's DiseaseReliable signal	9 Oct 2026Sasanlimab · Phase 1
Eli LillyLLY · NYSE	68 assets: 28 approved, 13 Ph 3, 12 Ph 2, 14 Ph 1, 1 other	eloralintidePhase 3 · ObesityReliable signal	Nov 2026tirzepatide · Phase 3
AbbVieABBV · NYSE	57 assets: 19 approved, 10 Ph 3, 13 Ph 2, 14 Ph 1, 1 other	TavapadonPhase 3 · Parkinson's DiseaseReliable signal	Nov 2026Budigalimab · Phase 2
Bristol-Myers SquibbBMY · NYSE	49 assets: 20 approved, 10 Ph 3, 11 Ph 2, 8 Ph 1	AzacitidinePhase 3 · Acute Myeloid LeukemiaPartial signal	5 Oct 2026Xanomeline/trospium chloride · Phase 3
Johnson & JohnsonJNJ · NYSE	49 assets: 32 approved, 7 Ph 3, 7 Ph 2, 3 Ph 1	SeltorexantPhase 3 · Major Depressive DisorderReliable signal	30 Oct 2026bleximenib · Phase 1
Merck & Co.MRK · NYSE	34 assets: 12 approved, 14 Ph 3, 5 Ph 2, 3 Ph 1	EnlicitidePhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal	9 Oct 2026Alimatravir · Phase 1
AmgenAMGN · Nasdaq	31 assets: 19 approved, 8 Ph 3, 1 Ph 2, 3 Ph 1	ABP 938Phase 3 · Age-Related Macular DegenerationReliable signal	31 Oct 2026Sotorasib · Phase 1
Regeneron PharmaceuticalsREGN · Nasdaq	31 assets: 6 approved, 8 Ph 3, 14 Ph 2, 3 Ph 1	itepekimabPhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signal	7 Oct 2026dupilumab · Phase 3
Gilead SciencesGILD · Nasdaq	20 assets: 9 approved, 6 Ph 3, 4 Ph 2, 1 Ph 1	AmbrisentanPhase 3 · HypertensionReliable signal	Dec 2026Sacituzumab Govitecan · Phase 3
BiogenBIIB · Nasdaq	17 assets: 9 approved, 3 Ph 3, 4 Ph 2, 1 Ph 1	LitifilimabPhase 3 · Systemic Lupus ErythematosusReliable signal	20 Oct 2026Litifilimab · Phase 2/3
Ionis PharmaceuticalsIONS · Nasdaq	17 assets: 6 approved, 5 Ph 3, 5 Ph 2, 1 Ph 1	PelacarsenPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal	Dec 2026Donidalorsen · Phase 3
Arrowhead PharmaceuticalsARWR · Nasdaq	16 assets: 1 approved, 3 Ph 3, 9 Ph 2, 3 Ph 1	OlpasiranPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal	Dec 2026SRP-1004 · Phase 1
Vertex PharmaceuticalsVRTX · Nasdaq	16 assets: 7 approved, 3 Ph 3, 5 Ph 2, 1 Ph 1	PovetaciceptPhase 3 · Myasthenia Gravis	30 Oct 2026Vanzacaftor / tezacaftor / deutivacaftor · Phase 3
Alnylam PharmaceuticalsALNY · Nasdaq	14 assets: 6 approved, 4 Ph 3, 3 Ph 2, 1 Ph 1	ZilebesiranPhase 3 · HypertensionReliable signal	12 Oct 2026Cemdisiran · Phase 3
ViatrisVTRS · Nasdaq	11 assets: 10 approved, 1 Ph 3	sildenafilPhase 3 · HypertensionPartial signal	None on record
BioMarin PharmaceuticalBMRN · Nasdaq	10 assets: 7 approved, 2 Ph 3, 1 Ph 2	INZ-701Phase 3 · Chronic Kidney DiseaseWeak signal	14 Oct 2026INZ-701 · Phase 1
IncyteINCY · Nasdaq	10 assets: 6 approved, 4 Ph 3	INCA033989Phase 3 · Essential Thrombocythemia	9 Oct 2026Ruxolitinib · Phase 3
Azurity PharmaceuticalsPrivate	7 assets: 7 approved	Approved assets only	Sep 2027Zonisamide (Zonisade) · Approved
Axsome TherapeuticsAXSM · Nasdaq	6 assets: 3 approved, 2 Ph 3, 1 Ph 2	AXS-14Phase 3 · Fibromyalgia	Dec 2026Solriamfetol · Phase 3
BiohavenBHVN · NYSE	6 assets: 5 Ph 3, 1 Ph 2	BHV-1400Phase 3 · Chronic Kidney Disease	Nov 2026Opakalim · Phase 1
XencorXNCR · Nasdaq	6 assets: 2 Ph 2, 4 Ph 1	XmAb5871Phase 2 · Systemic Lupus ErythematosusPartial signal	Feb 2027XmAb819 · Phase 1
Acadia PharmaceuticalsACAD · Nasdaq	4 assets: 2 approved, 1 Ph 3, 1 Ph 2	ACP-204Phase 3 · Alzheimer's Disease	Aug 2027ACP-211 · Phase 2
Corcept TherapeuticsCORT · Nasdaq	4 assets: 2 approved, 2 Ph 2	miricorilantPhase 2 · MASH / NASHWeak signal	30 Oct 2026miricorilant · Phase 1
CytokineticsCYTK · Nasdaq	4 assets: 1 approved, 2 Ph 3, 1 other	Omecamtiv mecarbilPhase 3 · Heart FailureReliable signal	Sep 2027Omecamtiv mecarbil · Phase 3
Denali TherapeuticsDNLI · Nasdaq	4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1	BIIB122 / DNL151 (LRRK2 inhibitor)Phase 3 · Parkinson's DiseasePartial signal	Feb 2027DNL628 · Phase 1
ModernaMRNA · Nasdaq	4 assets: 2 approved, 1 Ph 3, 1 Ph 2	Intismeran AutogenePhase 3 · Non-Small Cell Lung Cancer	31 Dec 2026elasomeran · Approved
Rhythm PharmaceuticalsRYTM · Nasdaq	4 assets: 1 approved, 3 Ph 2	LB54640Phase 2 · ObesityPartial signal	31 Oct 2026setmelanotide · Phase 2
Spyre TherapeuticsSYRE · Nasdaq	4 assets: 4 Ph 2	SPY001Phase 2 · Ulcerative Colitis	31 Oct 2026SPY072 · Phase 2
iCell Gene TherapeuticsPrivate	4 assets: 2 Ph 2, 2 Ph 1	ICG318Phase 2 · Systemic Lupus Erythematosus	31 Dec 2027ICG318 · Phase 1
AlectorALEC · Nasdaq	3 assets: 2 Ph 2, 1 other	AL002Phase 2 · Alzheimer's Disease	15 Sep 2028GSK4527226 (AL101) · Phase 2
Biomea FusionBMEA · Nasdaq	3 assets: 1 Ph 2, 2 Ph 1	BMF-219Phase 2 · Type 2 DiabetesPartial signal	Mar 2027BMF-219 · Phase 2
Esperion TherapeuticsPrivate	3 assets: 3 approved	Approved assets only	None on record
Intra-Cellular TherapiesPrivate	3 assets: 1 approved, 2 Ph 2	Lenrispodun (ITI-214)Phase 2 · Parkinson's DiseasePartial signal	16 Mar 2027ITI-1284 · Phase 2
Ligand PharmaceuticalsLGND · Nasdaq	3 assets: 3 approved	Approved assets only	1 Mar 2027ensifentrine · Phase 2
MannKind CorporationMNKD · Nasdaq	3 assets: 3 approved	Approved assets only	Mar 2027Afrezza · Phase 2
OPKO HealthOPK · Nasdaq	3 assets: 2 approved, 1 Ph 2	OPK-88006Phase 1/2 · MASH / NASH	Oct 2027Extended-release calcifediol · Phase 2
Palatin TechnologiesPTN · NYSE	3 assets: 1 Ph 3, 2 Ph 2	PL9643Phase 3 · Dry Eye Disease	None on record
United TherapeuticsUTHR · Nasdaq	3 assets: 2 approved, 1 Ph 3	RalinepagPhase 3 · HypertensionReliable signal	Dec 2026Ralinepag · Phase 3
Viking TherapeuticsVKTX · Nasdaq	3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1	VK2735Phase 3 · ObesityReliable signal	1 Jul 2027VK2735 · Phase 3
vTv TherapeuticsVTVT · Nasdaq	3 assets: 1 Ph 3, 2 Ph 2	cadisegliatinPhase 3 · Type 1 Diabetes	Apr 2027cadisegliatin · Phase 3
ADARx PharmaceuticalsPrivate	2 assets: 1 Ph 3, 1 Ph 1	TelitaciceptPhase 3 · Systemic Lupus ErythematosusReliable signal	31 Dec 2026Telitacicept · Phase 3
Akebia TherapeuticsAKBA · Nasdaq	2 assets: 1 approved, 1 Ph 2	PraliciguatPhase 2 · Chronic Kidney Disease	Jun 2027Praliciguat · Phase 2
Akros PharmaPrivate	2 assets: 1 Ph 3, 1 Ph 2	EnarodustatPhase 3 · Chronic Kidney DiseaseReliable signal	Jun 2027Enarodustat · Approved
AlumisALMS · Nasdaq	2 assets: 1 Ph 3, 1 Ph 1	EnvudeucitinibPhase 3 · PsoriasisReliable signal	1 Dec 2027Envudeucitinib · Phase 2
Anavex Life SciencesAVXL · Nasdaq	2 assets: 1 Ph 3, 1 Ph 2	BlarcamesinePhase 3 · Alzheimer's DiseaseReliable signal	None on record
Corbus PharmaceuticalsCRBP · Nasdaq	2 assets: 1 Ph 3, 1 Ph 1	CRB-701Phase 3 · Cervical Cancer	16 Jan 2027CRB-701 · Phase 1/2
Currax PharmaceuticalsPrivate	2 assets: 2 approved	Approved assets only	Jan 2029naltrexone/bupropion · Approved
Harmony BiosciencesHRMY · Nasdaq	2 assets: 1 approved, 1 Ph 3	Clemizole (EPX-100)Phase 3 · Epilepsy	1 Nov 2026Clemizole (EPX-100) · Phase 3
Inhibikase TherapeuticsIKT · Nasdaq	2 assets: 2 Ph 2	Risvodetinib (IkT-148009)Phase 2 · Parkinson's DiseasePartial signal	None on record
Kailera TherapeuticsKLRA · Nasdaq	2 assets: 2 Ph 3	HRS-7535Phase 3 · ObesityReliable signal	Dec 2026HRS-7535 · Phase 2
KardiganKARD · Nasdaq	2 assets: 1 Ph 3, 1 Ph 2	DanicamtivPhase 3 · Heart FailurePartial signal	Dec 2026Tonlamarsen · Phase 2
Kyntra BioKYNB · Nasdaq	2 assets: 1 Ph 3, 1 Ph 2	RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal	30 Oct 2027Roxadustat · Phase 3
Lexicon PharmaceuticalsLXRX · Nasdaq	2 assets: 1 approved, 1 Ph 2	PilavapadinPhase 2 · Diabetic Peripheral Neuropathic PainPartial signal	Jan 2027Sotagliflozin (Inpefa) · Phase 3
Liquidia CorporationLQDA · Nasdaq	2 assets: 1 approved, 1 Ph 3	L606Phase 3 · Hypertension	Feb 2027Treprostinil (Yutrepia, Liquidia) · Phase 2
MetaViaMTVA · Nasdaq	2 assets: 1 Ph 2, 1 Ph 1	DA-1241Phase 2 · Type 2 DiabetesPartial signal	9 Nov 2026DA-1726 · Phase 1
Mirador TherapeuticsPrivate	2 assets: 2 Ph 2	MT-201Phase 2 · Ulcerative Colitis	12 Nov 2026MT-201 · Phase 1
NImmune BiopharmaPrivate	2 assets: 1 Ph 2, 1 Ph 1	omilancorPhase 2 · Ulcerative ColitisPartial signal	None on record
Nektar TherapeuticsNKTR · Nasdaq	2 assets: 1 Ph 3, 1 Ph 2	rezpegaldesleukinPhase 3 · Atopic DermatitisPartial signal	May 2028rezpegaldesleukin · Phase 3
Neumora Therapeutics, Inc.NMRA · Nasdaq	2 assets: 1 Ph 1, 1 other	NMRA-323511Phase 1 · Alzheimer's DiseasePartial signal	None on record
Nuravax, Inc.Private	2 assets: 1 Ph 2, 1 Ph 1	AV-1959RPhase 2 · Alzheimer's DiseasePartial signal	1 Apr 2027DUVAX · Phase 1
OrsoBioPrivate	2 assets: 1 Ph 2, 1 Ph 1	TLC-2716Phase 2 · Atherosclerotic Cardiovascular Disease	None on record
RANI TherapeuticsRANI · Nasdaq	2 assets: 1 Ph 2, 1 Ph 1	PG-102Phase 2 · ObesityPartial signal	1 Dec 2026PG-102 · Phase 1
VIVUSPrivate	2 assets: 1 approved, 1 Ph 3	Extended-release tacrolimus (VI-0106)Phase 3	31 May 2028Extended-release tacrolimus (VI-0106) · Phase 3
Veru Inc.VERU · Nasdaq	2 assets: 1 Ph 3, 1 Ph 2	enobosarmPhase 3 · ObesityPartial signal	Oct 2027enobosarm · Phase 2
Voyager TherapeuticsVYGR · Nasdaq	2 assets: 1 Ph 2, 1 other	VY7523Phase 1/2 · Alzheimer's Disease	May 2027VY7523 · Phase 1/2
Windtree TherapeuticsWINT · OTC	2 assets: 1 Ph 3, 1 other	IstaroximePhase 2/3 · Heart FailurePartial signal	None on record
ABVC BioPharmaABVC · Nasdaq	1 asset: 1 Ph 2	PDC-1421Phase 2 · Major Depressive DisorderPartial signal	28 Feb 2028PDC-1421 · Phase 1/2
ADvantage TherapeuticsPrivate	1 asset: 1 Ph 2	AD04Phase 2 · Alzheimer's Disease	Dec 2026AD04 · Phase 2
ARCA Biopharma (Genvara Biopharma)Private	1 asset: 1 Ph 2	BucindololPhase 2 · Heart FailurePartial signal	None on record
ARS Pharmaceuticals, Inc.SPRY · Nasdaq	1 asset: 1 approved	Approved assets only	None on record
Aardvark TherapeuticsPrivate	1 asset: 1 Ph 3	ARD-101Phase 3 · ObesityPartial signal	None on record
Acumen PharmaceuticalsABOS · Nasdaq	1 asset: 1 Ph 2	SabirnetugPhase 2 · Alzheimer's DiseasePartial signal	None on record
Adiso TherapeuticsPrivate	1 asset: 1 Ph 1	ADS051Phase 1 · Ulcerative ColitisPartial signal	None on record
AgeneBioPrivate	1 asset: 1 Ph 3	AGB101Phase 2/3 · Alzheimer's DiseasePartial signal	None on record
AllRock BioPrivate	1 asset: 1 Ph 2	ROC-101Phase 2 · Hypertension	Mar 2027ROC-101 · Phase 2
Allyx TherapeuticsPrivate	1 asset: 1 Ph 1	BMS-984923Phase 1 · Alzheimer's DiseasePartial signal	None on record
AltimmuneALT · Nasdaq	1 asset: 1 Ph 3	pemvidutidePhase 3 · MASH / NASHPartial signal	30 Sep 2027pemvidutide · Phase 2
AltruBioPrivate	1 asset: 1 Ph 2	ALTB-268Phase 2 · Ulcerative Colitis	None on record
Alzamend NeuroALZN · Nasdaq	1 asset: 1 Ph 2	AL001Phase 1/2 · Alzheimer's Disease	Dec 2026AL001 · Phase 1/2
AlzheonPrivate	1 asset: 1 Ph 3	ValiltramiprosatePhase 3 · Alzheimer's DiseasePartial signal	None on record
Annovis Bio (NYSE American: ANVS)ANVS · NYSE American	1 asset: 1 Ph 3	BuntanetapPhase 3 · Alzheimer's DiseasePartial signal	Dec 2027Buntanetap · Phase 3
Anwita Biosciences, Inc.Private	1 asset: 1 Ph 1	AWT020Phase 1 · Non-Small Cell Lung Cancer	30 Apr 2028AWT020 · Phase 1
Areteia TherapeuticsPrivate	1 asset: 1 Ph 3	dexpramipexolePhase 3 · AsthmaPartial signal	None on record
Artery TherapeuticsPrivate	1 asset: 1 Ph 1	CS6253Phase 1 · Alzheimer's DiseasePartial signal	None on record
Athos TherapeuticsPrivate	1 asset: 1 Ph 2	ATH-063Phase 2 · Ulcerative ColitisPartial signal	14 Dec 2028ATH-063 · Phase 2
Avobis BioPrivate	1 asset: 1 Ph 2	AVB-114Phase 2 · Crohn's Disease	None on record
BioCardiaBCDA · Nasdaq	1 asset: 1 Ph 3	CardiAMPPhase 3 · Heart FailurePartial signal	1 Apr 2027CardiAMP · Phase na
BioVie Inc. (NASDAQ: BIVI)BIVI · Nasdaq	1 asset: 1 Ph 3	BezisterimPhase 3 · Alzheimer's DiseasePartial signal	None on record
Biomed IndustriesPrivate	1 asset: 1 Ph 2	NA-931Phase 2 · ObesityPartial signal	15 Aug 2027NA-931 · Phase 2
Capricor TherapeuticsCAPR · Nasdaq	1 asset: 1 Ph 3	deramiocelPhase 3 · Duchenne Muscular Dystrophy	None on record
Cardurion PharmaceuticalsPrivate	1 asset: 1 Ph 2	TovinontrinePhase 2 · Heart FailurePartial signal	None on record
Cenna BiosciencesPrivate	1 asset: 1 Ph 1	8M2DPhase 1 · Alzheimer's Disease	Sep 20278M2D · Phase 1
Cirius TherapeuticsPrivate	1 asset: 1 Ph 3	MSDC-0602KPhase 3 · Type 2 DiabetesPartial signal	None on record
Cognition TherapeuticsCGTX · Nasdaq	1 asset: 1 Ph 2	ZervimesinePhase 2 · Alzheimer's DiseasePartial signal	31 May 2027Zervimesine · Phase 2
ConSynance TherapeuticsPrivate	1 asset: 1 Ph 2	CSTI-500Phase 2 · Obesity	Jun 2027CSTI-500 · Phase 2
Direct BiologicsPrivate	1 asset: 1 Ph 3	ExoFloPhase 3 · Ulcerative ColitisWeak signal	Jun 2027ExoFlo · Phase 2
ERX PharmaceuticalsPrivate	1 asset: 1 Ph 2	ERX1000Phase 2 · ObesityPartial signal	May 2027ERX1000 · Phase 2
GeNOPrivate	1 asset: 1 Ph 2	Inhaled Nitric Oxide (GeNO NITROSYL platform)Phase 2	None on record
Gossamer BioGOSS · Nasdaq	1 asset: 1 Ph 3	SeralutinibPhase 3 · Pulmonary Arterial Hypertension	Dec 2026Seralutinib · Phase 3
Gyre TherapeuticsGYRE · Nasdaq	1 asset: 1 Ph 1	F230Phase 1 · Hypertension	None on record